Woburn,
MA, April 11, 2000
“This financing further validates the
technologies being developed by AlphaGene and will permit us to
continue investing in proprietary technologies leading toward
disease pathways and new drug discoveries,” stated Donald J.
McCarren, Ph.D., President and Chief Executive Officer. “One of
our major objectives with this placement is to augment our knowledge
and expand our patent position based on full-length genes and
functionality of our large gene inventory.”
AlphaGene has developed a very rich gene inventory
with over 150 cDNA libraries, primarily from human tissue.
Approximately 20 human tissues are represented including brain,
cardiovascular, skin and liver. About 55% of the gene inventory is
from the human brain, both adult and fetal and 45% is from
non-neurological human tissues. This inventory includes sequence
information on over 300,000 cDNA’s.
Building upon its patented core technologies,
AlphaGene has developed an integrated platform that includes gene
arraying on biochips for identifying differentially expressed genes
in disease or other cell states. AlphaGene is currently developing a
50,000-gene microarray to be used as an internal reagent and
commercial screening tool. AlphaGene employs specialized assays and
sophisticated bioinformatics to aid in the identification of
critical disease-specific targets. AlphaGene is privately owned and
is located in Woburn, MA.
Except
for historical information, the matters discussed in this news
release may be considered "forward-looking" statements
within a meaning of Section 27A of the Securities Act of 1933, as
amended. Such statements include its declaration regarding the
intent, belief or current expectation of the Company and its
management. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve a number of risks and uncertainties that could
materially effect actual results.
For
more information, please view our website at www.alphagene.com
or contact
AlphaGene, Inc. at (781) 933-4446.
